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Abstract
Background: Blepharospasm (BSP) is a type of focal dystonia characterized by
involuntary orbicularis oculi spasms that are usually bilateral, synchronous, and
symmetrical. Despite strong evidence for genetic contributions to BSP, progress
in the field has been constrained by small cohorts, incomplete penetrance, and late
age of onset. Although several genetic etiologies for dystonia have been identified
through whole-exome sequencing (WES), none of these are characteristically asso-
ciated with BSP as a singular or predominant manifestation.
Methods: We performed WES on 31 subjects from 21 independent pedigrees
with BSP. The strongest candidate sequence variants derived from in silico analy-
ses were confirmed with bidirectional Sanger sequencing and subjected to cose-
gregation analysis.
Results: Cosegregating deleterious variants (GRCH37/hg19) in CACNA1A (NM_
001127222.1: c.7261_7262delinsGT, p.Pro2421Val), REEP4 (NM_025232.3:
c.109C>T, p.Arg37Trp), TOR2A (NM_130459.3: c.568C>T, p.Arg190Cys), and
ATP2A3 (NM_005173.3: c.1966C>T, p.Arg656Cys) were identified in four inde-
pendent multigenerational pedigrees. Deleterious variants in HS1BP3 (NM_
022460.3: c.94C>A, p.Gly32Cys) and GNA14 (NM_004297.3: c.989_990del,
p.Thr330ArgfsTer67) were identified in a father and son with segmental cranio-
cervical dystonia first manifest as BSP. Deleterious variants in DNAH17, TRPV4,
CAPN11, VPS13C, UNC13B, SPTBN4, MYOD1, and MRPL15 were found in two
or more independent pedigrees. To our knowledge, none of these genes have pre-
viously been associated with isolated BSP, although other CACNA1A mutations
have been associated with both positive and negative motor disorders including
ataxia, episodic ataxia, hemiplegic migraine, and dystonia.
Conclusions: Our WES datasets provide a platform for future studies of BSP
genetics which will demand careful consideration of incomplete penetrance, pleio-
tropy, population stratification, and oligogenic inheritance patterns.
*These authors contributed equally to this work.
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1 | INTRODUCTION
Dystonia is defined as a movement disorder characterized
by sustained or intermittent muscle contractions causing
abnormal, often repetitive, movements, postures, or both
(Albanese et al., 2013). In general, adult- or late-onset dys-
tonia without evidence of overt degeneration or structural
lesions of the nervous system is referred to as isolated dys-
tonia and can be inherited in an autosomal-dominant fash-
ion with reduced penetrance. The most common forms of
focal dystonia are cervical dystonia and blepharospasm
(BSP). Blepharospasm (BSP) (OMIM: 606798) is charac-
terized by involuntary orbicularis oculi spasms that are usu-
ally bilateral, synchronous, and symmetrical (Defazio et al.,
2015). Review of BSP epidemiological data provides
prevalence estimates ranging from 16 to 133 per million
(Defazio, Abbruzzese, Livrea, & Berardelli, 2004). BSP is
significantly more common in females (>2F:1M) with a
mean age of onset at approximately 55 years (O’Riordan
et al., 2004). In comparison to cervical and laryngeal dys-
tonia, BSP is more likely to spread to other body parts
(Weiss et al., 2006). Most commonly, BSP spreads to con-
tiguous craniocervical segments (lower face, masticatory
muscles, and neck). The term segmental craniocervical dys-
tonia is applied to the combination of BSP and dystonia of
other head and neck muscles (LeDoux, 2009). Herein,
BSP-plus (BSP+) will be used to denote subjects with BSP
who exhibit subsequent spread to other anatomical seg-
ments (LeDoux, 2009; Waln & LeDoux, 2011). Sensory
tricks or geste antagonistes are highly specific to dystonia,
reported in a high percentage of patients with BSP, and
can facilitate the diagnosis of BSP (Defazio, Hallett, Jin-
nah, & Berardelli, 2013). However, without valid genetic
biomarkers, the diagnosis of BSP can be difficult, even for
experienced clinicians (Defazio et al., 2013).
Although rare cases of isolated BSP have been linked to
THAP1 (OMIM 609520) mutations (LeDoux et al., 2012;
Vemula et al., 2014), the genetic underpinnings of this
focal dystonia remain largely unknown. In one study, 233
relatives of 56 probands with primary BSP were examined
and 27% had a first-degree relative affected by BSP or
other dystonia (Defazio, Martino, Aniello, Masi, Abbruzz-
ese, et al., 2006). Using an autosomal dominant model,
penetrance was approximately 20% in pedigrees with BSP
(Defazio, Martino, Aniello, Masi, Abbruzzese, et al., 2006;
Defazio, Martino, Aniello, Masi, Gigante, et al., 2006). For
comparison, penetrance of the classic DGAG mutation in
TOR1A (OMIM 605204, DYT1) is 30%–40% (Bressman
et al., 2000). Approximately 10% of subjects in large
biorepositories of isolated dystonia have a first- or second-
degree relative with dystonia (LeDoux et al., 2016; Vemula
et al., 2013, 2014; Xiao et al., 2010, 2011, 2012). Even
though late-onset isolated dystonia has a considerable “her-
itable” component, large pedigrees adequately powered for
linkage analysis are rare. Conversely, small multiplex pedi-
grees with 2 or 3 affected individuals are not uncommon.
In six published clinical series, 1st-degree relatives of
probands with isolated dystonia were subjected to examina-
tion (Defazio, Livrea, Guanti, Lepore, & Ferrari, 1993;
Defazio, Martino, Aniello, Masi, Abbruzzese, et al., 2006;
Leube, Kessler, Goecke, Auburger, & Benecke, 1997; Sto-
janovic, Cvetkovic, & Kostic, 1995; Waddy, Fletcher,
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Harding, & Marsden, 1991). Within these reported families,
overall phenotypic concordance-discordance was approxi-
mately 50%–50%. However, discordant pedigrees are rela-
tively more common in probands with BSP than cervical
dystonia (Defazio, Berardelli, & Hallett, 2007). An exam-
ple of phenotypic discordance would be the presence of
BSP in a proband and cervical dystonia in one of the pro-
band’s siblings. Phenotype concordance is the presence of
a single anatomical distribution of dystonia (e.g., BSP) in
all affected family members.
Herein, we report the results of whole-exome sequenc-
ing (WES) of 31 subjects from 21 independent pedigrees
with BSP and/or BSP+, the largest collection of BSP pedi-
grees examined to date. Our series includes both concor-
dant and discordant pedigrees. Our results will facilitate a
better understanding of the genetic underpinnings of iso-
lated BSP and other, mainly adult-onset, dystonias. A col-
lection of in silico tools, including dbNSFP (Dong et al.,
2015; Liu, Jian, & Boerwinkle, 2011; Liu, Wu, Li, & Boer-
winkle, 2016), dbscSNV (Jian, Boerwinkle, & Liu, 2014),
Combined Annotation-Dependent Depletion (CADD;
Kircher et al., 2014), REVEL (Ioannidis et al., 2016), and
MutationTaster (Schwarz, Cooper, Schuelke, & Seelow,
2014) were used to identify and prioritize candidate
sequence variants. Putative disease-associated variants were
confirmed with bidirectional Sanger sequencing, followed
by cosegregation analysis. Cosegregating deleterious vari-
ants in CACNA1A (OMIM 601011), REEP4 (OMIM
609349), TOR2A (OMIM 608052), ATP2A3 (OMIM
601929), HS1BP3 (OMIM 609359), GNA14 (OMIM
604397) and DNAH17 (OMIM 610063) were identified in
single pedigrees.
2 | MATERIALS AND METHODS
2.1 | Ethical compliance
All human studies were conducted in accordance with the
Declaration of Helsinki with formal approval from the
University of Tennessee Health Science Center Institutional
Review Board (IRB; 01-07346-FB, 05-08331-XP, and 14-
03320-XP) and ethics committees of all participating cen-
ters. All subjects gave written informed consent for genetic
analyses and disclosure of medical information.
2.2 | Subjects
Subjects in this study were examined by at least one neu-
rologist with subspecialty expertise in movement disorders.
Subjects were asked to perform specific tasks, including
holding their eyes open, opening and closing their eyes
gently, opening and closing their eyes forcefully, along
with additional verbal and postural maneuvers designed to
capture masticatory, laryngeal or cervical involvement. A
clinical diagnosis of definite BSP was given to subjects
that exhibited increased blinking and stereotyped, bilateral
and synchronous orbicularis oculi spasms inducing narrow-
ing/closure of the eyelids (Defazio et al., 2013). Subjects
with isolated episodes of increased eyelid blinking were
given a diagnosis of possible BSP. Each affected or possi-
bly affected family member was queried for the presence
of sensory tricks. WES was completed on a total of 31 sub-
jects from 21 pedigrees from the United States, Poland,
and Italy (Table 1). Prior to WES, pathogenic variants in
THAP1, GNAL (OMIM 139312) and Exon 5 of TOR1A
were excluded as previously described (LeDoux et al.,
2012; Vemula et al., 2013; Xiao et al., 2009, 2010). Two
pedigrees were African–American and 19 pedigrees were
Caucasian of European descent. The results of WES on the
proband of African–American pedigree 10908 were previ-
ously reported (Xiao, Thompson, Vemula, & LeDoux,
2016) and deposited in Sequence Read Archive
(SRX1790848).
2.3 | Whole-exome sequencing
The concentration and quality of genomic DNA (gDNA)
extracted from peripheral blood were examined with a
NanoDrop ND-1000 (Thermo Scientific), the Qubit
dsDNA BR Assay Kit (Thermo Scientific) and agarose gel
electrophoresis. DNA was then forwarded to Otogenetics
or Beijing Genomics Institute (BGI) for additional in-house
quality control assessments prior to WES.
For WES at Otogenetics, 3 lg of genomic DNA
(gDNA) was sheared to yield 100–450 bp fragments. In-
solution whole-exome capture and massively parallel
sequencing was performed using the Agilent SureSelectXT
All Exon Kit 51 Mb. Enriched DNA fragments were
sequenced on Illumina’s HiSeq 2500 platform as paired-
end 100–125 base-pair reads. On average, over 95% of
exons were covered at >209. The percentage of exome
coverage was based on exons targeted by the 51 Mb All
Exon v4 Kit which incorporates Consensus Coding
Sequence (CCDS), NCBI Reference Sequence (RefSeq)
and GENCODE annotations.
For WES at BGI, the gDNA samples were fragmented
by Covaris, and, after two rounds of bead purification, the
resulting gDNA fragments were mainly distributed between
200 and 400 bp. Then, AdA 50- and 30-adaptors were
ligated to the 50- and 30-ends of the fragments, respectively.
The AdA adaptor-ligated fragments were amplified by
PCR, and the PCR products were used for exon capture. A
58.95 Mb region was targeted for capture. The captured
exon fragments were purified by DynabeadsM-280 strepta-
vidin bead purification and were further amplified by
another round of PCR. Then, the PCR products were
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TABLE 1 BSP and BSP+ subjects examined with whole-exome sequencing
Subject Age
Age of
onset Sex Ethnicity
BSP
family
history Anatomical distribution Select candidate genes
10012 77 60 F Caucasian No Segmental dystonia (BSP,
oromandibular, lower face, cervical)
KCNH4, CHRNA7, SPTBN4, ATP13A2
10014 70 47 F Caucasian No Segmental dystonia (BSP,
oromandibular, lower face)
KCNG4, PLP1, KCNS1, ACLY, VPS13C
10035 67 55 F Caucasian No Segmental dystonia (BSP,
oromandibular, lower face, cervical)
TRPV4, TBP, IMP4, UBXN4
10036 69 66 F Caucasian No Segmental dystonia (BSP, cervical) HK1, PRUNE2, NUMBL, MRPL15
10043-I-1 83 57 M Caucasian Yes Segmental dystonia (BSP,
oromandibular, lower face, cervical)
GNA14, HS1BP3, NEFH, RWDD2A
10043-II-2 51 45 M Caucasian Yes Segmental dystonia (BSP,
pharyngeal, laryngeal,
cervical), Parkinsonism
GNA14. HS1BP3, NEFH, RWDD2A
10064 60 47 M Caucasian Yes Segmental dystonia (BSP,
oromandibular, lower face, cervical)
HECW2, CDH4, RABL2B, AP4B1, SCN3A
10076 62 61 F Caucasian No Segmental dystonia (BSP, cervical) CAPN11, REEP2, MYO1B, DNAH17,
ATP13A2
10178 59 20 M Caucasian Yes BSP ZZEF1, KCNA5, MUYOD1, MRPL15
10193 77 69 F Caucasian Yes BSP IGSF21, MYOD1
10274-II-3 56 45 M AA Yes Segmental dystonia (BSP, cervical) TRPV4, WDFY3, ZFYVE9
10274-II-6 50 50 F AA Yes BSP TRPV4, WDFY3, ZFYVE9
10455 58 48 F Caucasian Yes Segmental dystonia (BSP,
oromandibular, lower face, cervical)
CADPS, SNPH, ATP2B1, SLC12A2,
CAPN11, VSP13DC, SPTBN4, BTNL3
10908-II-3 66 48 M AA Yes Segmental dystonia (BSP,
oromandibular, lower face, cervical)
REEP4
10908-III-9 33 30 M AA Yes BSP REEP4
25056 70 59 F Caucasian Yes Segmental dystonia (BSP,
oromandibular, lower face,
arm tremor)
ABCA2, MYT1L
25069 61 56 M Caucasian Yes BSP (with arm tremor) LRP1B, PCDHGA3, LAMA1, UNC13B,
ATP13A2
25215 57 54 F Caucasian Yes BSP (with arm tremor) AGAP1, EPS15L1, SCN1A, UNC13B, TOP3B
45263 78 77 M Caucasian Yes BSP INO80, DNAH17
85020 66 50 F Caucasian Yes BSP LRP1, GCH1, DDHD2, UNK
NG0362-II-2 57 39 M Caucasian Yes BSP CACNA1A
NG0362-I-1 76 67 M Caucasian Yes BSP CACNA1A
NG0362-III-1 35 NA M Caucasian Yes BSP CACNA1A
NG0369-II-2 80 58 F Caucasian Yes BSP TOR2A, PCDH15, GTDC1
NG0369-III-2 52 NA F Caucasian Yes BSP TOR2A, PCDH15, GTDC1
NG0369-III-6 46 NA F Caucasian Yes BSP TOR2A, PCDH15, GTDC1
NG0450-IV-3 80 53 F Caucasian Yes BSP TRPV4, SERPINB9, CNTNAP2
NG0450-V-4 64 40 F Caucasian Yes BSP TRPV4, SERPINB9, CNTNAP2
NG0450-V-6 51 38 M Caucasian Yes Writer’s cramp TRPV4, SERPINB9, CNTNAP2
NG1072-II-5 72 NA M Caucasian Yes BSP ATP2A3
NG1072-IV-2 24 21 F Caucasian Yes Cervical dystonia ATP2A3
AA, African–American; NA, not available.
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circularized and the resulting double strand (ds) circles
digested with Ecop15. Among these digested fragments,
small fragments were collected after bead purification. Sim-
ilar to the AdA adaptor ligation, AdB adapters were ligated
to both ends of the purified fragments and the fragments
were then used for single strand (ss) circularization. The
resulting ss circles were the final library products used on
the CG Black Bird sequencing platform. Finally, high-
throughput sequencing was performed for each captured
library.
2.4 | Read mapping
Sequence reads (FASTQ) from Illumina (Otogenetics) were
mapped to the human reference genome (NCBI build 37.1)
with NextGENe (SoftGenetics). Using the consolidation
and elongation functions of NextGENe, instrument sequenc-
ing errors were reduced and sequence reads were lengthened
prior to variant analysis. The condensation tool polished the
data for adequate coverage by clustering similar reads with a
unique anchor sequence. Using this process, short reads
were lengthened and reads with errors were filtered or cor-
rected. To maximize the probability of detecting causal vari-
ants, all base changes occurring in ≥4 reads in any
individual sample were classified as variants for downstream
analyses. An Overall Mutation score of 5 was used as a cut-
off to filter read errors and reduce the effects of allelic
imbalances. The Overall Mutation score is generated via a
proprietary algorithm (SoftGenetics) to provide an empirical
estimation of the likelihood that a given variant call is gen-
uine and not an artifact of sequencing or alignment errors.
This score is based on the concept of Phred scores, where
quality scores are logarithmically linked to error probabili-
ties. With NextGENe software, intergenic and deep intro-
nic (≥12 nt from splice sites) variants were eliminated prior
to downstream in silico analyses.
Complete Genomics (BGI) developed high-speed map-
ping software capable of aligning read data to reference
sequences. Using GRCh37 as the reference, the mapping is
tolerant of small variations from a reference sequence, such
as those caused by individual genomic variation, read
errors, or unread bases. To support assembly of larger vari-
ations, including large-scale structural changes or regions
of dense variation, each arm of a DNA Nanoball (DNB) is
mapped separately, with mate pairing constraints applied
after alignment. Initially, mapping reads to the human ref-
erence genome is a constrained process that does not allow
for insertions and deletions. All mate-pair constraint-satis-
fying paired-end mappings are used to detect small vari-
ants. DNBs are then filtered and individual reads are
optimized. Optimization collects reads likely to lie in
regions of interest, using mate alignment information and
performs local de novo assemblies.
2.5 | Single-nucleotide variants (SNVs) and
small insertions and deletions (INDELS)
First, a list of shared variants was generated for pedigrees
with two or more affected subjects analyzed with WES.
For Otogenetics Illumina data, we eliminated SNVs and
INDELS with minor allele frequencies (MAFs) ≥0.001 in
the Exome Aggregation Consortium (ExAC; Lek et al.,
2016) database or 1000 Genomes (1KG), variants with
unbalanced reads (variant allele < 25%), and regions cov-
ered by <5 reads. For BGI data, we eliminated SNVs and
INDELs with MAFs ≥0.001 in 1 KG or Exome Variant
Server (EVS). Of note, both BGI and Otogenetics outputs
contain inverted major/minor allele classifications for a
subset of sequence variants (minor allele: MAF <0.001 or
>0.999). All nonsynonymous SNVs were analyzed with
dbNSFP (versions 3.3 to 3.5; Liu et al., 2016), CADD
(Kircher et al., 2014) and REVEL (Ioannidis et al., 2016).
Nonsynonymous SNVs with MetaLR (Dong et al., 2015)
ranking scores >0.75, CADD phred scores >15, or
REVEL scores >0.5 were retained for further evaluation.
Nonsense SNVs, frameshift variants, synonymous SNVs,
splice site SNVs, and other SNVs and INDELS (30 and 50
untranslated region [UTR] variants, downstream variants,
intronic variants, noncoding variants and upstream vari-
ants) were analyzed with CADD +/ MutationTaster2
(Schwarz, Rodelsperger, Schuelke, & Seelow, 2010). Non-
sense SNVs, frameshift variants, synonymous SNVs,
splice site SNVs, other SNVs and INDELs with
CADD_phred scores >15 were retained for further evalua-
tion. All splice-site SNVs were analyzed with
dbscSNV1.1 (Jian et al., 2014), which contains precom-
puted ensemble scores, Ada and RF, for all potential
splice-site SNVs computed using AdaBoost and random
forests, respectively. Splice-site SNVs with Ada scores
>0.6 or RF scores >0.6 were retained for further evalua-
tion. Particular attention was paid to variants within the
DYT13 (1p36.32-p36.13; Bentivoglio et al., 1997; Valente
et al., 2001) and DYT21 (2q14.3-q21.3) loci. The DYT13
locus was identified via linkage analysis of a large 3-gen-
eration pedigree with craniocervical and other anatomical
distributions of dystonia. Similarly, the DYT21 locus was
defined through linkage analysis of a Swedish kindred
with apparently autosomal dominant inheritance of dysto-
nia which included BSP is several affected subjects (Fors-
gren, Holmgren, Almay, & Drugge, 1988; Norgren,
Mattson, Forsgren, & Holmberg, 2011). Detailed methods
for analysis of BGI and Otogenetics information can be
found in the Data S1.
REVEL, MetaLR and CADD scores were used to prior-
itize nonsynonymous missense variants for additional scru-
tiny whereas CADD and ExAC Probability of Loss-of-
Function (LoF) intolerance (pLI) scores were used to
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prioritize nonsense SNVs and frameshift INDELs. Muta-
tionTaster was also used for analysis of small INDELs
which are not scored by REVEL or MetaLR. Each cate-
gory of variant (nonsynonymous, synonymous, splice-site,
nonsense, frameshift, other INDELs, and other SNVs) was
ranked by in silico scores of deleteriousness. Population
frequencies for the highest scoring variants were addition-
ally assessed with genome Aggregation Database (gno-
mAD), NHLBI Exome Sequencing Project (ESP) Exome
Variant Server (EVS) with particular attention to racial sub-
categories. All NCBI databases were queried with gene
symbols and the names of encoded proteins. Particular
attention was paid to data contained in PubMed, ClinVar,
OMIM, and BioSystems. OMIM was searched for allelic
disorders/phenotypes. MARRVEL and its link outs were
used to explore available data related to animal models of
homologs, genomic structural variants (DGV and DECI-
PHER), gene expression (GTex), and protein expression
(ProteinAtlas). Gene expression was also analyzed with
Allen Brain Atlas and BioGPS. Candidate genes were elim-
inated if not expressed in at least one “motor” region of
the brain (striatum, cerebellum or frontal motor cortex).
UniProt was used to access protein–protein interactions,
sites of known or predicted posttranslational modifications
and known or putative protein functions. Multiple sequence
alignments were performed with Clustal Omega. A subset
of candidate pathogenic variants was confirmed with bidi-
rectional Sanger sequencing to exclude next generation
sequencing read errors. After Sanger confirmation, cosegre-
gation was assessed in individual pedigrees.
2.6 | Copy number variant analysis
CNVkit (Talevich, Shain, Botton, & Bastian, 2016), a
Python library and command-line software toolkit to infer
and visualize copy number variants (CNVs) from targeted
DNA sequencing data, was used to detect CNVs in WES
data generated by Otogenetics on the Illumina platform.
CNVkit was designed for use on hybrid capture sequencing
data where off-target reads are present and can be used to
improve copy number estimates. CNVkit normalizes read
counts to a pooled reference and corrects for three main
sources of bias: GC content, target footprint size, and repet-
itive sequences. For this purpose, Otogenetics provided us
with WES data from 15 random subjects of unknown race
and unknown geographic region of origin sequenced as
part of unrelated projects using the Agilent SureSelectXT
All Exon Kit 51 Mb for exome capture and sequenced on
Illumina’s HiSeq 2500 platform.
CNVkit reports log2 copy ratios. Assuming pure sam-
ples and germline mutations, the log2 ratio should be 1.0
for a deletion mutation and infinity if both alleles are
deleted. The log2 ratio is 0.585 for duplications and 1.0 for
triplications. The relationship between the estimated copy
number and the true copy number depends on a number of
factors including read depth and number of probes covering
a region of interest.
2.7 | Sanger sequencing
PCR was performed using 40 ng of peripheral blood
gDNA along with 200 nmol/L of each primer (Table S1)
in a 10-ll reaction volume with HotStarTaq Plus DNA
polymerase from Qiagen. The following cycling conditions
were employed: 95°C for 15 min; 35 cycles at 95°C for
10 s, 58°C for 30 s, and 72°C for 30 s.
2.8 | PCR validation of copy number
variants
Quantitative PCR (qPCR) was used for initial assessment
of a random selection of predicted CNVs identified with
CNVkit. Primers and probes for qPCR were designed with
Roche’s Universal Probe Library to cover (Table S1).
qPCR was performed using 20 ng of template DNA and
200 nmol/L of each primer in a 10-ll reaction volume with
the LightCyclerTM 480 system and Universal Taqman
probes (Roche). The following cycling conditions were
employed: 95°C for 5 min; 45 cycles at 95°C for 10 s,
58°C for 30 s, and 72°C for 12 s. Copy numbers were cal-
culated against an endogenous control, HLCS, holocarboxy-
lase synthetase. All assays were carried out in triplicate and
means were used for calculating fold changes.
Digital PCR (dPCR) was then used for confirmation of
select deletion and duplication CNVs identified with
CNVkit. Literature mining as described for SNVs and
small lNDELs was used to select genes with deletion log2
scores of 0.75 to 1.25 and covered by ≥4 probes, or
genes with duplication log2 scores of 0.385 to 0.835 and
covered by ≥4 probes. Primers and probes (FAM dye-
labeled) were designed via Roche’s Universal Probe
Library to encompass the estimated deletion regions
(Table S1). The TaqMan copy number reference assay
(Applied Biosystems 4403326) contained RNase P-specific
FIGURE 1 Blepharospasm (BSP) and BSP+ Pedigrees. Pedigrees with two or more affected individuals. Arrows, probands. Arrowheads,
other family members analyzed with whole-exome sequencing. White symbol, unaffected. Black symbols, BSP, BSP+ or other anatomical
distribution of dystonia. Gray symbols, possibly affected
606 | TIAN ET AL.
TIAN ET AL. | 607
forward and reverse primers and VIC dye-labeled TAMRA
hydrolysis probe. RNase P, a single copy gene, is used as
the reference for this work (Qin, Jones, & Ramakrishnan,
2008).
Reaction mixtures (4.0 ll) containing TaqMan gene-
expression master mix (Life Technologies), 20X GE sam-
ple loading reagent (Fluidigm 85000746), 20X gene-speci-
fic assays, 20X TaqMan copy number reference assay
(Applied Biosystems) and 1.2 ll target gDNA (20 ng/ll)
was pipetted into each loading inlet of a 48.770 dPCR
array (Fluidigm). The BioMark IFC controller MX (Flu-
idigm) was used to uniformly partition the reaction from
the loading inlet into the 770 9 0.84 nl chambers and
dPCR was performed with the Fluidigm BioMark System
for Genetic Analysis. The Fluidigm dPCR software was
used to count gene copy numbers. The quality thresholds
were manually set specific to each assay, but consistent
across all panels of the same assay. The CNV calculation
is based on “relative copy number” so that apparent dif-
ferences in gene copy numbers in different samples are
not distorted by differences in sample amounts. The rela-
tive copy number of a gene (per genome) is expressed as
the ratio of the copy number of a target gene to the copy
number of a single copy reference gene in the sample. By
using assays for the two genes (the gene of interest and
the reference gene) with two fluorescent dyes on the same
Digital Array IFC, we are able to simultaneously quanti-
tate both genes in the same DNA sample. The ratio of
these two genes is the relative copy number of the gene
of interest.
2.9 | Data availability
Primers (Table S1), WES variants examined with Sanger
sequencing (Table S2), and potential CNVs examined with
qPCR (Table S3) are included in Data S1. Comprehensive
WES variant analysis for each pedigree is included in indi-
vidual Excel workbooks (10012, 10014, 10035, 10036,
10043, 10064, 10076, 10178, 10193, 10274, 10455,
10908, 25056, 25069, 25215, 45263, 85020, NB0362_BGI,
NG0369, NG0450, and NG1072_BGI).
3 | RESULTS
3.1 | BSP and BSP+ pedigrees
Whole-exome sequencing was completed on 31 subjects
from 21 distinct pedigrees with either concordant or discor-
dant BSP and BSP+ phenotypes (Table 1, Figures 1 and 2,
Data S1). Exome coverage is provided in Tables 2 and 3.
Depth of coverage was ≥109 and ≥209 for over 97.5%
and 95% of the 31 exomes. Numbers of total and filtered
variants are provided in Table 4.
3.2 | CACNA1A INDEL in a three-generation
pedigree with BSP
A novel CACNA1A INDEL (c.7261_7262delinsGT [NM_
001127222.1], p.Pro2421Val [NP_001120694.1]) was
identified in three males and one asymptomatic female
family member from a three-generation pedigree with BSP
FIGURE 2 Flow chart for whole-
exome sequencing data analysis. Analysis
of exomes sequenced by Beijing Genomics
Institute (BGI) and Otogenetics.
Otogenetics (Illumina) reads were mapped
in house. BGI did not provide raw read
data
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(Figure 3, Tables 1, 5, 8 and S2; Data S1). Complete
Genomics outputted this variant as two contiguous SNVs.
This INDEL is not reported in control databases (ExAC,
1KG or gnomAD) and predicted to be deleterious by
CADD (Phred score = 19.51) and MutationTaster (disease
causing, probability value: 1.0). However, two contiguous
SNVs are reported in gnomAD (19:13318386 and
19:13318387) with very similar allele frequencies (211/
118674 and 207/119456). Analysis of read data suggests
that the majority of these SNVs are, in fact, part of the
c.7261-7262delinsGT INDEL. The 19:13318386G/A vari-
ant is present at relatively high frequency in the Finnish
TABLE 2 Exome coverage otogenetics (Illumina)
Subjects
Exon coverage
Mapped reads Reads in exons (% of mapped)≥103 average ≥203 average ≥503 average
NG0369-II-2 182,985 (98.71%) 180,451 (97.20%) 158,686 (85.48%) 40,359,835 27,882,382 (69.08%)
NG0369-III-2 183,285 (98.73%) 181,151 (97.58%) 164,561 (88.64%) 46,282,001 31,819,162 (68.75%)
NG0369-III-6 183,245 (98.71%) 181,036 (97.52%) 163,455 (88.05%) 45,818,817 31,595,919 (68.95%)
NG0450-V-4 183,339 (98.76%) 181,430 (97.73%) 167,149 (90.04%) 48,910,931 33,455,111 (68.41%)
NG0450-V-6 183,262 (98.72%) 180,540 (97.25%) 160,781 (86.61%) 44,674,009 30,667,372 (68.64%)
NG0450-IV-3 182,910 (98.53%) 180,235 (97.09%) 157,051 (84.60%) 38,518,463 26,893,126 (69.81%)
10012 183,177 (98.67%) 179,968 (96.94%) 151,762 (81.75%) 43,360,914 30,295,318 (69.86%)
10014 183,345 (98.76%) 180,745 (97.36%) 157,291 (84.73%) 45,133,245 30,866,426 (68.38%)
10035 183,449 (98.82%) 181,074 (97.54%) 159,805 (86.08%) 47,593,537 32,451,839 (68.18%)
10036 183,377 (98.78%) 180,492 (97.22%) 155,013 (83.50%) 43,455,430 29,831,744 (68.64%)
10043-II-2 182,658 (98.39%) 179,067 (96.46%) 149,939 (80.77%) 36,183,050 23,982,731 (66.28%)
10064 181,329 (97.67%) 174,416 (93.95%) 135,925 (73.22%) 31,906,497 23,887,178 (74.87%)
10076 181,156 (97.58%) 175,038 (94.29%) 137,975 (74.32%) 30,495,728 22,423,886 (73.53%)
10043-I-1 183,249 (98.71%) 181,131 (97.57%) 166,235 (89.54%) 50,010,351 34,444,302 (68.87%)
10178 183,260 (98.72%) 180,253 (97.10%) 157,001 (84.57%) 44,071,238 29,754,633 (67.51%)
10193 182,958 (98.55%) 179,944 (96.93%) 154,912 (83.44%) 40,787,072 27,819,791 (68.20%)
10274-II-3 183,257 (98.72%) 180,866 (97.43%) 162,983 (87.79%) 44,609,530 29,931,870 (67.09%)
10274-II-6 183,149 (98.66%) 181,247 (97.63%) 167,458 (90.2%) 54,207,882 36,192,334 (66.76%)
10455 183,030 (98.59%) 180,044 (96.98%) 156,811 (84.47%) 48,944,558 30,884,770 (63.10%)
10908-II-3 183,169 (98.67%) 181,017 (97.51%) 164,543 (88.63%) 47,084,143 32,159,148 (68.30%)
10908-III-9 183,065 (98.6%) 183,065 (97.35%) 163,351 (87.99%) 45,541,395 30,924,196 (67.90%)
25056 183,204 (98.68%) 180,273 (97.11%) 153,853 (82.87%) 45,212,675 30,858,562 (68.25%)
25069 182,022 (98.05%) 176,604 (95.13%) 142,875 (76.96%) 33,328,570 24,217,999 (72.66%)
25215 182,687 (98.41%) 179,180 (96.52%) 150,346 (80.99%) 37,771,677 25,469,621 (67.47%)
45263 183,442 (98.81%) 181,182 (97.61%) 163,127 (87.87%) 48,922,580 33,055,765 (67.56%)
85020 183,190 (98.68%) 180,786 (97.38%) 163,888 (88.28%) 58,478,165 35,599,118 (60.87%)
TABLE 3 Exome coverage BGI (Complete Genomics)
Subject
Bases on
targets
Targets
covered
≥ 13
Targets
covered
≥ 53
Targets
covered
≥ 103
Targets
covered
≥ 203
NG0362-III-1 58,970,115 99.56% 98.68% 97.64% 95.28%
NG1072-II-5 58,970,115 99.57% 98.72% 97.70% 95.36%
NG0362-II-2 58,970,115 99.56% 98.66% 97.60% 95.25%
NG0362-I-1 58,970,115 99.59% 98.76% 97.73% 95.32%
NG1072-IV-2 58,863,950 99.54% 98.66% 97.62% 95.27%
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population (1.49E-02) with a much lower allele frequency
of (6.76E-04) in non-Finnish Europeans and quite rare in
other racial populations. The identified amino acid substi-
tution is located in the C-terminal, intracellular domain of
the encoded voltage-dependent P/Q-type calcium channel
subunit a-1A, which is conserved among mammals (Fig-
ure 3). We did not screen other variants for cosegregation
given previously established associations between CAC-
NA1A and dystonia. Five SNVs had CADD_phred scores
>15 and REVEL scores >0.5 but none had a MetaLR
score >0.75, REVEL score >0.75 and CADD_phred score
>30. A frameshift INDEL in MMP28 with a CADD_phred
score of 34 is reported in ExAC and gnomAD. Four non-
sense SNVs had CADD_phred scores >30 but two are
reported in ExAC and gnomAD and none seem biologi-
cally plausible candidates.
3.3 | REEP4 missense variant
A nonsynonymouse SNV in REEP4 (c.109C>T [NM_
025232.3], p.Arg37Trp [NP_079508.2]) was identified in
seven subjects with BSP+ or BSP and one asymptomatic
female family member from a three-generation African–
American pedigree (Figure 4, Tables 1, 5, 8 and S2; Data
S1). This variant is present at very low frequency in gno-
mAD and predicted to be deleterious by in silico analysis,
including CADD (phred score = 34), REVEL (0.767),
MetaLR (0.960), and MutationTaster2 (disease causing,
probability value: 1.0). In gnomAD, this variant is not pre-
sent in 15,290 African alleles. The p.Arg37Trp variant
alters an amino acid that is highly conserved among verte-
brates as shown by the multiple pairwise alignments gener-
ated with Clustal Omega (Figure 4).
TABLE 4 Total and filtered variants
Pedigree (#
subjects)
# common variants
(SNVs + INDELs)
Potentially pathogenic variants
Platform
Nonsynonymous
SNVs
Nonsense
SNVs
Synonymous
SNVs
Splice
site
SNVs
Frame-
shift
Other
SNVs &
indels CNVs
NG0362 (3) 30,704 68 4 9 5 7 32 NA Complete
Genomics
NG1072 (2) 31,417 63 1 8 4 5 42 NA Complete
Genomics
NG0369 (3) 3,771 60 2 8 2 14 232 217 Illumina
NG0450 (3) 3,749 48 3 8 0 13 214 145 Illumina
10043 (2) 4,233 82 3 10 1 20 184 46 Illumina
10274 (2) 5,462 141 6 10 2 25 26 110 Illumina
10908 (2) 4,665 79 2 9 0 19 227 46 Illumina
10012 (1) 6,511 118 3 9 1 6 243 60 Illumina
10014 (1) 7,255 173 7 21 2 29 272 69 Illumina
10035 (1) 7,016 141 7 16 4 23 251 38 Illumina
10036 (1) 6,954 137 3 4 2 19 234 41 Illumina
10064 (1) 14,196 258 5 36 9 30 347 50 Illumina
10076 (1) 14,357 178 9 29 1 17 340 29 Illumina
10178 (1) 7,865 127 8 21 2 33 239 14 Illumina
10193 (1) 7,136 129 7 20 1 22 213 42 Illumina
10455 (1) 7,551 167 7 24 1 25 262 80 Illumina
25056 (1) 7,196 170 6 16 4 23 254 61 Illumina
25069 (1) 9,064 145 4 22 3 23 254 11 Illumina
25215 (1) 7,017 176 5 19 5 23 256 52 Illumina
45263 (1) 9,340 139 2 19 3 25 277 25 Illumina
85020 (1) 7,984 151 3 22 4 31 246 77 Illumina
SNVs, single nucleotide variants; INDELs, small deletion and insertions; CNVs, copy number variants; NA, not available.
SNVs and INDELs with (MAFs) >0.001 (1 KG or EVS for Complete Genomics/BGI; and ExAC for Illumina/Otogenetics). Nonsynonymous SNVs: CADD phred
score >15 or MetaLR >0.75 or REVEAL >0.5. Nonsense SNVs: CADD phred score >15. Synonymous SNVs: CADD phred score >15. Splice-site SNVs: CADD
phred score >15 or ada_score >0.6 or rf_score >0.6. Frame shift: CADD phred score >15. Other SNVs & INDELs: CADD phred score >15.
CNVs: all generated via analysis with CNVkit.
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3.4 | TOR2A missense variant
A TOR2A nonsynonymous SNV (c.568C>T [NM_130459.
3], p.Arg190Cys [NP_569726.2]) was identified in three
subjects with BSP and three asymptomatic members from a
four generation pedigree (Figure 5; Tables 1, 5, 8 and S2;
Data S1). This variant is present at low frequency in ExAC
(5.84e-05) and predicted to be deleterious by in silico anal-
ysis including CADD (phred score = 34), REVEL (0.548),
MetaLR (0.811), and MutationTaster2 (disease causing,
probability value: 1.0). The p.Arg190Cys variant alters an
amino acid that is highly conserved among vertebrates as
shown by the multiple pairwise alignments generated with
Clustal Omega (Figure 5). TOR2A encodes torsin family 2
member, a known interactor with dystonia-associated pro-
tein torsinA (BioGRID). Nonsense variants in PCDH15
and GTDC1 were also detected in all three affected
subjects and have CADD_phred scores >30 but pLI scores
of 0. PCDH15 and GTDC1 have 28 and 15 LoF variants
in ExAC, respectively. FRG1 variants detected with WES
are likely due to mapping errors caused by related genomic
sequences.
3.5 | ATP2A3 missense variant
An ATP2A3 nonsynonymous SNV (c.1966C>T [NM_
005173.3], p.Arg656Cys [NP_001120694.1]) was identified
in five affected subjects, one possibly affected subject, and
three asymptomatic members of discordant Family NG1072
(Figure 5; Tables 1, 5, 8 and S2; Data S1). Predicted to be
highly deleterious by all in silico analysis (CADD_phred
score = 34, REVEL score = 0.872, MetaLR = 0.99175,
MutationTaster2 [disease causing, probability value: 1.0]),
this variant (rs140404080) is reported in ExAC (5.51E-04)
FIGURE 3 CACNA1A INDEL Identified in a Multigenerational Pedigree with BSP. (a) Family NG0362 with BSP. Three affected (I-1, II-2
and III-1) individuals were selected for WES. +/+, wild-type; +/-, heterozygous for CACNA1A c.7261_7262delinsGT. (b) Electropherograms of
unaffected family member (II-3) and subject with BSP (II-2). (c) Multiple sequence alignment shows evolutionary conservation of Pro2421
among mammals. (d) Location of disease-associated variants in the a-1A subunit of P/Q type, voltage-dependent, calcium channels: (1)
Thr666Met variant linked to familial hemiplegic migraine and early-onset cerebellar atrophy (Naik et al., 2011; Ophoff et al., 1996), (2) variant
(c.3772delC) predicted to cause a frameshift and truncated protein or, more likely, nonsense-mediated decay in a man with interictal BSP and
episodic ataxia type 2 (Spacey et al., 2005), (3), splice-site variant associated with episodic ataxia type 2 (Ophoff et al., 1996), (4) Ile1811Leu
variant associated with familial hemiplegic migraine (Ophoff et al., 1996), (5), Glu2080Lys variant linked to sporadic hemiplegic migraine
(Thomsen et al., 2008), (6), CAG expansion associated with spinocerebellar ataxia type 6 (SCA6) and dystonia (Kuo et al., 2017; Sethi &
Jankovic, 2002; Zhuchenko et al., 1997), (7) Pro2421Val variant associated with BSP in our multigenerational pedigree, (8), Pro2479Leu
associated with sporadic hemiplegic migraine (Thomsen et al., 2008), and (9) His2481Gln associated with sporadic hemiplegic migraine
(Thomsen et al., 2008)
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and gnomAD (6.63E-04) with a population frequency of
approximately 0.1%. The Arg656Cys variant alters an amino
acid that is highly conserved among vertebrates (Figure 5).
Another candidate variant in MYH13 (rs7807826) did not
completely cosegregate with dystonia in this pedigree
(Table S2, Data S1). Moreover, expression of MYH13 is
mainly restricted to the extrinsic eye muscles. A nonsense
variant in NOS2 (NM_000625.4: c.2059C>T, p.Arg687*;
CADD_phred = 36) was shared by the two affected individ-
uals analyzed with WES but NOS2 is expressed at only low
levels in brain and Nos2-/- mice have not been reported to
manifest positive or negative motor signs. ATP2A3 is highly
expressed in cerebellar Purkinje cells (Allen Brain Atlas) and
is a member of the P-type ATPase superfamily that includes
the gene (ATP1A3) causally associated with rapid-onset
dystonia-Parkinsonism (DYT12).
3.6 | GNA14 and HS1BP3 variants in
pedigree with BSP+ and Parkinsonism
A novel HS1BP3 nonsynonymous SNV (c.94C>A [NM_
022460.3], p.Gly32Cys [NP_071905.3]) was found in a
father and son with severe BSP+ (Family 10043; Figure 6;
Tables 1, 5, 8 and S2; Data S1). The deceased father had
two brothers with clinical diagnoses of Parkinson disease
(PD). The proband has BSP, mild lower facial dystonia,
cervical dystonia and laryngeal respiratory dystonia. The
laryngeal respiratory dystonia required treatment with a tra-
cheostomy. The proband developed levodopa-responsive
Parkinsonism approximately 15 years after the onset of his
dystonia. An ioflupane I-123 dopamine transporter scan
showed nigrostriatal denervation. The c.94C>A [NM_
022460.3] variant is not reported in ExAC, 1KG or gno-
mAD, and is predicted to be deleterious by all in silico
analysis (CADD_phred score = 34, REVEL = 0.454,
MetaLR = 0.803). Of note, a different variant in HS1BP3
(p.A265G) was previously associated with essential tremor
(ET), a disorder potentially related to the adult-onset dysto-
nias through common genetics (Higgins et al., 2005). The
p.Gly32Cys variant alters an amino acid that is highly con-
served among vertebrates (Figure 6).
A GNA14 frameshift variant (c.989_990del [NM_
004297.3], p.Thr330ArgfsTer67 [NP_004288.1]) was also
identified in the same pedigree (Family 10043) and is pre-
sent at low frequency in gnomAD (1.23E-05) (Figure 6;
Tables 1, 5, and 8 and S2; Data S1). This GNA14 variant
is predicted to be deleterious by CADD (phred score = 36)
and MutationTaster2 (disease causing, probability value:
1.0). GNA14 encodes G protein subunit a14 which shows
modest expression in brain, particularly the striatum and
cerebellum (Human Protein Atlas). Recently, somatic muta-
tions in GNA14 have been linked to congenital and spo-
radic vascular tumors (Lim et al., 2016). Mutations inT
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another G protein, Ga(olf), are associated with various
anatomical distributions of mainly adult-onset dystonia.
3.7 | DNAH17 variants found in pedigree
and isolated subject with BSP
Deleterious variants in DNAH17 were identified in two
brothers with BSP and one isolated case of BSP (Figure 7;
Tables 1, 6, 8 and S2, Data S1). Both variants are present
at low frequency in ExAC and gnomAD. DNAH17 encodes
dynein axonemal heavy chain 17. The FANTOM5 dataset
reports expression of DNAH17 in testes and brain (hip-
pocampus, caudate and cerebellum; Kawaji, Kasukawa,
Forrest, Carninci, & Hayashizaki, 2017). DNAH17 has not
yet been linked to any other neurological or non-neurological
disease. A roundworm homolog (dhc-1) of human
DNAH17 is involved in cytokinesis, microtubule-based
movement, mitotic spindle organization, meiotic nuclear
division and nervous system development (MARRVEL).
3.8 | Copy number variants
CNVkit called from 11 to 217 CNVs per shared exome.
Assessing randomly selected CNVs with qPCR showed
high discordancy (Table S3), particularly for variants that
did not have log2 ratios near 1.0. We then focused on
CNVs with log2 ratios compatible with a single-copy gain
(~0.585) or single-copy loss (1.0) using dPCR. Deletions
in LILRA3 were confirmed in three unrelated subjects with
BSP (Table 7). LILRA3 (OMIM 604818) deletions are
common in the general population and may increase risk
for HIV infection and some autoimmune disorders
(Ahrenstorf et al., 2017; Du et al., 2015). A deletion in
BTNL3 (OMIM 606192) and duplications in SLC2A14
(OMIM 611039), SLC2A3 (OMIM 138170), TOP3B
(OMIM 603582), and UNK (616375) were identified in
single exomes (Tables 7 and 8). UNK is expressed at high
levels in brain (Allen Brain Atlas, BioGPS, and The
Human Protein Atlas) and plays an important role in the
development of neuronal morphology. Two UNK duplica-
tions are reported in ExAC. To date, UNK has not been
linked to any medical disorder (OMIM). Copy number
analysis of GOLGA8A (Chr15) was compromised by the
presence of pseudogenes and a homolog with very close
sequence similarity on Chr15.
3.9 | Other candidate genes found in two or
more pedigrees
The strongest candidate variants (CADD_phred >20 and
MutationTaster2 = disease causing  MetaLR >0.75) were
compared among all exomes from all pedigrees to identify
common candidate genes. Three variants in TRPV4 (OMIM
605427) were identified in three independent pedigrees.
TRPV4 has been associated with several medical disorders
including autosomal dominant spinal muscular atrophy.
However, all three variants are reported in ExAC and gno-
mAD at significant frequencies. The same SNV in
CAPN11 (OMIM 604822; NM_007058.3: c.425T>C,
p.Leu142Pro) found in two independent pedigrees is
reported once in gnomAD and has high CADD_phred (32),
MetaLR (0.982) and REVEL (0.918) scores. CAPN11
encodes calpain 11, an intracellular calcium-dependent cys-
teine protease that shows highest expression in testis. One
FIGURE 4 REEP4 Variant in
African–American Pedigree with BSP+ and
BSP. (a) Family 10908 with BSP+ and
BSP. Two affected (II-3 and III-9)
individuals were selected for WES. +/+,
wild-type; +/-, heterozygous for REEP4
c.109C>T. (b) Electropherograms of
unaffected family member (II-2) and subject
with BSP+ (II-3). (c) Multiple sequence
alignment shows evolutionary conservation
of Arg37 among vertebrates
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nonsense variant in VPS13C (OMIM 608879) was found in
a single subject with BSP and a rare missense variant in
VPS13C was found in another subject with BSP. Both of
these VPS13C variants are predicted to be highly deleteri-
ous to protein function. Loss of VPS13C causes mitochon-
drial dysfunction and has been linked to autosomal
recessive PD (Lesage et al., 2016). Moreover, VPS13C
variants may increase risk for PD, in general (Foo et al.,
2017), and, dystonia may share genetic underpinnings with
PD (LeDoux et al., 2016). Other candidate genes (SPTBN4
[OMIM 606214], MRPL15 [OMIM 611828], UNC13B
[605836], and MYOD1 [159970]) shared by two pedigrees
show moderate-to-high expression in motor regions of
brain. Mice carrying recessive loss-of-function Sptbn4
mutations manifest ataxia, motor neuropathy, deafness and
tremor (Parkinson et al., 2001).
FIGURE 5 TOR2A and ATP2A3 Variants in Multigenerational Pedigrees with BSP. (a) Family NG0369 with BSP. Three affected (II-2, III-
2 and III-6) individuals were selected for WES. +/+, wild-type; +/, heterozygous for TOR2A c.568C>T. (b) Electropherograms of unaffected
family member (II-6) and subject with BSP (II-2). (c) Multiple sequence alignment shows evolutionary conservation of Arg190 among
vertebrates. (d) Discordant pedigree NG1072 with BSP, cervical dystonia, and arm dystonia. Two affected individuals were selected for WES (II-
2, IV-2). +/+, wild-type; +/, heterozygous for ATP23 c.1966C>T. White symbol, unaffected. Black symbol, BSP, BSP+ or other anatomical
distribution of dystonia. Gray symbol, possibly affected. (e) Electropherograms of unaffected family member (II-4) and subject with BSP (II-2).
(f) Multiple sequence alignment shows evolutionary conservation of Arg656 among vertebrates
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3.10 | DYT13 and DYT21 loci
Within the DYT13 locus (Chr1), three subjects harbored
ATP13A2 (OMIM 610513) variants. Subject 10012 was
found to have a missense variant (rs151117874,
CADD_phred = 22.4, REVEL = 0.497, MetaLR = 0.8657,
gnomAD = 21/272174 [3.67E-06], Data S1). Less deleteri-
ous synonymous (CADD_phred = 17.53) and missense
(CADD_phred = 21.1) variants were found in subjects
10076 and 25069, respectively (Table 1, Data S1). Recessive
mutations in ATP13A2 have been linked to Kufor–Rakeb
syndrome (Ramirez et al., 2006) and spastic paraplegia 78
(Estrada-Cuzcano et al., 2017), both of which may include
dystonia as a clinical manifestation. Variants in ATP13A2
may also contribute to oligogenic inheritance in PD (Lubbe
et al., 2016). In subject 10035, a deleterious variant within
the DYT21 (Chr2) locus was identified in IMP4 (OMIM
612981; rs146322628, CADD_phred = 29.3, MetaLR =
0.83, REVEL = 0.606, gnomAD = 5.1E-04, Data S1), and
deleterious variants in UBR4 (OMIM 609890; rs748114415,
CADD_phred = 23.3, REVEL = 0.188, MetaLR = 0.46,
MutationTaster2 = 0.81 [disease causing], gnomAD = 5.1E-
04, Data S1), and ARHGEF19 (OMIM 612496; rs144638812,
CADD_phred = 22.7, MetaLR = 0.64, REVEL = 0.11,
FIGURE 6 GNA14 and HS1BP3 Variants in Father and Son with BSP+. (a) Pedigree 10043. The proband has BSP+ and levodopa-
responsive Parkinsonism. His father had BSP+ and both were selected for WES. +/+, wild-type; +/, heterozygous for variants in GNA14 and
HS1BP3. (b) Electropherograms of unaffected family member (II-1) and proband (II-2) show GNA14 variant. (c) Multiple sequence alignment
shows evolutionary conservation of Thr330 among vertebrates. (d) Electropherograms of unaffected family member (II-1) and proband (II-2)
show HS1BP3 variant. (e) Multiple sequence alignment shows evolutionary conservation of Gly32 among vertebrates
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MutationTaster2 = 0.55 [disease causing], gnomAD = 2.3E-
04, Data S1) were identified in the DYT13 (Chr1) locus. To
date, IMP4 and ARHGEF19 have not been linked to a med-
ical disorder. IMP4 interacts with the U3 snoRNA complex
and is involved in nucleolar function (Granneman et al.,
2003). A missense variant in UBR4 (p.Arg5091His) was
found to segregate with episodic ataxia in a large Irish
pedigree (Conroy et al., 2014). UBR4 is expressed at high
levels in cerebellar Purkinje cells (Allen Brain Atlas),
interacts with calmodulin, colocalizes with ITPR1, and
may be involved in Purkinje cell calcium homeostasis
(Conroy et al., 2014). ARHGEF19 shows significant expres-
sion in cerebellar Purkinje cells (Allen Brain Atlas) and
zebrafish arhgef19 is involved in neural tube closure (Miles
et al., 2017).
4 | DISCUSSION
The molecular and cellular mechanisms underlying BSP
and other anatomical distributions of isolated dystonia
remain fragmentary. Accordingly, treatments for BSP are
entirely symptomatic (Pirio Richardson et al., 2017). Most
commonly, BSP patients are treated with injections of botu-
linum toxin although, in some series, almost 50% report
minimal improvement, no improvement or worsening of
BSP after injections of botulinum toxins (Fernandez et al.,
2014). Identification of genetic etiologies for BSP may per-
mit development of targeted disease-modifying therapeu-
tics. In this study, we used exome sequencing to explore
genetic contributions to BSP and provide a foundation for
future case–control studies of this important focal dystonia.
Although we do provide data suggesting potential roles
for CACNA1A, REEP4, TOR2A, ATP2A3, HS1BP3/GNA14,
DNAH17, TRPV4, CAPN11, VPS13C, UNC13B, SPTBN4,
MYOD1, and MRPL15 in the pathogenesis of BSP, the lim-
itations of our work should be bordered. First, we did not
identify a common cosegregating genetic etiology in more
than one pedigree. This points to the likely genetic hetero-
geneity of BSP but also suggests that one or more variants
identified herein cosegregated by chance alone. Unfortu-
nately, none of our pedigrees were powered to generate
LOD (logarithm [base 10] of odds) scores >3 thereby pre-
cluding the usage of linkage analysis for validation of
FIGURE 7 DHAH17 Variants in Pedigree and Isolated Subject with BSP. (a) Pedigree 45263 with BSP. +/+, wild-type; +/, heterozygous
for variant in DNAH17. (b) Electropherogram of proband (II-2) showing DNAH17 variant. (c) Multiple sequence alignment shows evolutionary
conservation of Pro3158 among vertebrates. (d) Electropherogram of subject 10076 showing c.13295G>A variant. (e) Multiple sequence
alignment shows evolutionary conservation of Arg4432 among vertebrates
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cosegregating variants. Second, several of the candidate
variants identified with WES are reported in population
databases (ExAC and gnomAD) with MAFs near the mini-
mal population prevalence of BSP. On the other hand,
noted MAFs are significantly lower than the maximal pop-
ulation prevalence of BSP with corrections for the mark-
edly reduced penetrance characteristic of isolated dystonia.
Furthermore, BSP and premonitory increased blinking may
be much more common in the general population than
commonly accepted (Conte et al., 2017). Thirdly, our
genetically heterogeneous cohort included Polish, Italian,
Caucasian–American and African–American pedigrees,
possibly reducing the probability of detecting variants
shared among pedigrees and singletons. Accordingly, fol-
low-up case–control analysis of individual variants identi-
fied herein will require careful attention to population
stratification and large sample sizes to confidently deter-
mine if variants in candidate genes are enriched in BSP.
Fourth, our prioritization of variants was predominantly dri-
ven by in silico predictions of deleteriousness and many
potentially pathogenic candidate variants were not con-
firmed with Sanger sequencing or subjected to cosegrega-
tion analysis. Fifth, WES will miss most repeat expansions
and does not access the mitochondrial genome. In this
regard, repeat expansions are a common cause of late-onset
neurological disease and mitochondrial mutations may
include dystonia as part of a more expansive neurological
phenotype (LeDoux, 2012). Furthermore, our approach to
CNV analysis was largely insensate to smaller structural
variants such as single exonic deletions. Despite these limi-
tations, our findings are compatible with common themes
in dystonia research (calcium signaling, Purkinje cells, and
dopaminergic signaling), point out potential genetic com-
mon ground with PD and ET, suggest a role for oligogenic
inheritance in BSP, and provide motivation for treating a
subset of BSP patients with acetazolamide.
CACNA1A is highly expressed in the cerebellum, partic-
ularly the Purkinje cell layer. Mutations in several genes
related to calcium signaling and homeostasis and expressed
in Purkinje cells have been causally associated with dysto-
nia in humans and mice (LeDoux, 2011). In fact, virtually
all genes associated with dystonia in spontaneous mutants
(tottering, stargazer, ophisthotonus, ducky, lethargic, wad-
dles, and wriggle) are involved in Purkinje cell Ca2+ sig-
naling (Canca1a, Cacng2, Itpr1, Cacna2d2, Cacnb4, and
Pmca2). In humans, autosomal-recessive mutations in HPCA
(OMIM 142622) cause childhood-onset dystonia and the
encoded protein, hippocalcin, is robustly expressed in Purk-
inje cells and serves as a Ca2+ sensor (Charlesworth et al.,
2015; Tzingounis, Kobayashi, Takamatsu, & Nicoll, 2007).
SVs in CACNA1A have been associated with a variety of
neurological disorders including episodic ataxia type 2,
familial hemiplegic migraine, spinocerebellar ataxia type 6
(SCA6), and various anatomical distributions of dystonia
such as benign paroxysmal torticollis of infancy and BSP
(Naik, Pohl, Malik, Siddiqui, & Josifova, 2011; Sethi & Jan-
kovic, 2002; Shin, Douglass, Milunsky, & Rosman, 2016;
Spacey, Materek, Szczygielski, & Bird, 2005; Thomsen
TABLE 7 Confirmation of CNV variants using Digital PCR of Genomic DNA
Patient ID Gene hg19 CNV Coordinates
Log2
Ratio
Digital PCR
Gene/
RNASE P CNV
10455 BTNL3 Chr5: 180416000–180429824 0.95 0.50 Deletion
10036 LILRA3 Chr19: 54801997–54804319 1.13 0.62 Deletion
10178 LILRA3 Chr19: 54801997–54804319 0.91 0.55 Deletion
10193 LILRA3 Chr19: 54801997–54804319 1.04 0.60 Deletion
25056 SLC2A14 Chr12: 7984292–8043706 0.53 1.52 Duplication
25056 SLC2A3 Chr12: 8074017–8088678 0.53 1.51 Duplication
25215 TOP3B Chr22: 22312829–22330136 0.57 1.41 Duplication
85020 UNK Chr17: 73808156–73820465 0.58 1.50 Duplication
25056 CLEC18B Chr16: 74443499–74452124 1.20 1.04 Normal
10036 CYP2A7 Chr19: 41381608–41386459 1.08 1.00 Normal
10036 LRRC49 Chr15: 71229066–71305260 0.92 1.05 Normal
10036 RRP7A Chr22: 42908850–42912408 0.97 1.01 Normal
25056 GOLGA8A Chr15: 34673679–34681975 0.93 1.45 Duplication
45263 GOLGA8A Chr15: 34677244–34681975 0.94 1.08 Normal
85020 GOLGA8A Chr15: 34677244–34681975 1.08 1.15 Normal
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et al., 2008). A notable percentage of patients with dystonia
due to mutations in CACNA1A show significant improve-
ment with acetazolamide (Spacey, 1993; Spacey et al.,
2005). Unfortunately, our pedigree was lost to follow-up and
none of the affected family members were treated with aceta-
zolamide. The a-1 subunit of P/Q type, voltage-dependent,
calcium channel harbors a polyglutamine expansion in its
C-terminal intracellular domain and the novel missense vari-
ant p.Pro2421Val identified in our pedigree with BSP is near
this expansion (Figure 3). In contrast, the previously
described BSP-variant was likely associated with nonsense-
mediated decay and haploinsufficiency (Spacey et al., 2005).
Mutations linked to familial hemiplegic migraine appear to
operate via gain-of-function mechanisms whereas the SCA6
polyglutamine repeat and loss-of-function mutations may
lead to neuronal cell death (Cain & Snutch, 2011). In this
context, it is worthy to note that reduced Purkinje cell density
was found in two individuals with BSP and cervical dystonia
(Prudente et al., 2013).
REEP4 is a microtubule-binding endoplasmic reticu-
lum and nuclear envelope protein (Schlaitz, Thompson,
Wong, Yates, & Heald, 2013). Depletion of REEP4 from
HeLa cells is associated with defective cell division and
proliferation of intranuclear membranes derived from the
nuclear envelope (Schlaitz et al., 2013). Similarly,
omega-shaped nuclear blebs have been used as a pheno-
typic measure of torsinA (encoded by TOR1A) dysfunc-
tion (Laudermilch et al., 2016). In Xenopus, loss of
REEP4 causes defects of nervous system development
and paralysis of embryos (Argasinska et al., 2009). Muta-
tions in REEP1 (OMIM 609139) and REEP2 (OMIM
609347) are associated with spastic paraplegia (SPG)
types 31 (SPG31), and 72 (SPG72). Although dystonia is
not a clinical feature typically reported in SPG31 and
SPG72 cases, dystonia is not uncommon in several other
SPGs, including SPG7, SPG15, SPG26, SPG35, and
SPG47 (van Gassen et al., 2012; Klebe, Stevanin, &
Depienne, 2015).
A DGAG deletion in Exon 5 of TOR1A was the first
SV to be linked to isolated dystonia (Ozelius et al., 1997).
TorsinA interacts with LAP1, a transmembrane protein
ubiquitously expressed in the inner nuclear membrane.
Recessive mutations of TOR1AIP1 (OMIM 614512) which
encodes LAP1 are associated with severe early-onset gener-
alized dystonia and progressive cerebellar atrophy (Dorboz
et al., 2014). Another torsinA interacting protein, torsin
family 2 member A (encoded by TOR2A) was found to
harbor a missense variant in one of our pedigrees with
BSP. Similar to the DGAG mutation in TOR1A, the pene-
trance of the p.Arg190Cys missense variant identified in
our pedigree was less than 50%. TOR2A is a member of
the human torsin gene family (Laudermilch et al., 2016;
Ozelius et al., 1999). TOR1A, TOR2A and TOR1AIP1 allT
A
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show relatively high expression in cerebellar Purkinje cells
(Allen Brain Atlas).
A nonsynonymous SNV in ATP2A3 (NM_005173.3:
c.1966C>T, p.Arg656Cys) was found in five definitely-
affected subjects from a discordant pedigree with BSP from
Italy. However, this variant was not detected in one possi-
bly affected family member with writer’s cramp. This could
be either a phenocopy or evidence against the causality of
ATP2A3. Furthermore, the p.Arg656Cys variant is present
at notably high frequency in gnomAD (183/276,114 alleles,
no homozygotes, 0.13% of 138,057 subjects). BSP is the
most common focal dystonia in Italy with a crude preva-
lence rate of 133 per million or 0.013%. Even with a pene-
trance of <20%, this suggests that p.Arg656Cys may not be
pathogenic or, at least, pathogenic in isolation, requiring
digenic inheritance of another pathogenic variant. On the
other hand, p.Arg656Cys is predicted to be highly deleteri-
ous, may contribute to other anatomical distributions of dys-
tonia, and, like ATP1A3, could be involved in the
etiopathogenesis of other neurological disorders such as
Parkinson disease, Alzheimer disease, and brain tumors
(Kawalia et al., 2017; Korosec, Glavac, Volavsek, & Rav-
nik-Glavac, 2009; Matak et al., 2016). In this regard,
ATP2A3 shows striking expression in cerebellar Purkinje
cells and dopaminergic neurons of the substantia nigra pars
compacta (Allen Brain Atlas). ATP2A3 encodes a sarcoplas-
mic/endoplasmic reticulum Ca2+ ATPase and disorders of
Purkinje cell (LeDoux, 2011) and dopaminergic (Surmeier,
Halliday, & Simuni, 2017) calcium homeostasis have been
linked to dystonia and Parkinson disease, respectively.
A small pedigree (Figure 6) with BSP+ and Parkinson-
ism harboring variants in HS1BP3 and GNA14 highlights
the distinct possibility of oligogenic inheritance in BSP and
other anatomical distributions of dystonia. In particular, all
of the exomes sequenced in this study harbored more than
one potentially pathogenic variant. Since most of our pedi-
grees were small and moderate numbers of variants showed
in silico evidence of deleteriousness, we did not assess
cosegregration for all of the identified candidate variants.
However, we determined that both GNA14 and HS1PB3
were attractive candidate genes. Guanine nucleotide-bind-
ing protein subunit alpha-14 (encoded by GNA14) interacts
with dynein, axonemal, light chain 4 (UniProt) which is
expressed at high levels in sperm and brain. GNA14
appears to play a key role in the genetic architecture under-
lying normal gray matter density (Chen et al., 2015) and a
GNA14 deletion mutation has been reported in a patient
with early-onset Alzheimer disease (Lazarczyk et al.,
2017). HS1BP3 shows moderate expression in brain (The
Human Protein Atlas), and, in cerebellum, appears at high-
est levels in Purkinje cells (Allen Brain Atlas). Multipoint
linkage analysis in four large pedigrees with ET identified
a critical region between loci D2S2150 and D2S220 on
Chr 2p which includes HS1BP3 (Higgins, Loveless, Janko-
vic, & Patel, 1998). The p.A265G HCLS1-binding protein
3 (HS1BP3) variant encoded by HS1BP3 is in linkage dise-
quilibrium with ET but is unlikely to be causal since it is
present at high frequency in the general population (Shatu-
nov et al., 2005). It remains unknown if other coding or
noncoding variants in HS1BP3 are causally related to the
pathogenesis of ET. HS1BP3 negatively regulates auto-
phagy (Holland et al., 2016), a cellular pathway closely
tied to several neurodegenerative disorders including PD
(Nash, Schmukler, Trudler, Pinkas-Kramarski, & Frenkel,
2017). In this regard, ET and PD may be related to adult-
onset dystonia through common genetics (De Rosa et al.,
2016; Dubinsky, Gray, & Koller, 1993; Hedera et al.,
2010; LeDoux et al., 2016; Louis et al., 2012; Straniero
et al., 2017).
Oligenic inheritance is caused by mutations in two or
more proteins with a functional relationship through direct
interactions, membership in a pathway, or coexpression in
a specific cell type. Given that functional groups of genes
tend to colocalize within chromosomes (Thevenin, Ein-
Dor, Ozery-Flato, & Shamir, 2014), the possibility of oli-
gogenic inheritance of variants found within a locus
defined by linkage analysis cannot be ignored. Our focused
analyses of the DYT13 and DYT21 loci provide genes and
variants for cosegregation analysis in these previously
detailed dystonia pedigrees and suggest that digenic or
higher-order oligogenic inheritance of variants within a dis-
ease-associated locus may be causal in some pedigrees and
isolated cases with BSP. In this context, cosegregating vari-
ants in CIZ1 and SETX were linked to cervical dystonia in
a large American pedigree (Xiao et al., 2012).
Blepharospasm exerts important effects on health-related
quality of life (Hall et al., 2006). Many patients with BSP
experience annoying dry eye symptoms and photophobia
(Hallett, Evinger, Jankovic, Stacy, & Workshop, 2008).
Oral medications such as anticholinergics and benzodi-
azepines are mildly beneficial in some subjects. Many
patients with BSP show moderate benefit from injections of
botulinum toxin. However, injections are expensive, painful
and may be denied by third-party payers. Although deep
brain stimulation has been used to treat some individuals
with BSP+ phenotypes, responses have been mixed (Reese
et al., 2011). Major advances in the treatment of BSP
demand a deeper understanding of its genetic etiopathogen-
esis. Our work provides a platform for follow-up case–con-
trol analyses of identified variants, evaluation of digenic
and higher-order oliogenic etiologies for BSP (Deltas,
2017), and generation of animal models to help assess the
pathogenicity of identified variants. Future work will
demand attention to the effects of genetic background, oli-
gogenic inheritance, pleiotropy, confounds of phenocopies,
and the limitations of WES.
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